Mason W Freeman
Overview
Explore the profile of Mason W Freeman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
3623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freeman M, Halvorsen Y, Bond M, Murphy B, Isaacsohn J
Clin Pharmacol Drug Dev
. 2024 Feb;
13(4):410-418.
PMID: 38311833
Baxdrostat is a selective small-molecule aldosterone synthase inhibitor in development for treatment of hypertension and chronic kidney disease. This phase 1, open-label, parallel-group study assessed the safety and pharmacokinetics (PK)...
2.
McMurray J, Solomon S, Lock J, Massaro J, Zhu F, Zhou W, et al.
Diabetes Obes Metab
. 2023 Dec;
26(3):971-979.
PMID: 38151752
Aim: To explore the risk of major adverse cardiovascular events (MACE) associated with exposure to bexagliflozin. Methods: The analysis included 4090 participants with type 2 diabetes (T2D) enrolled in nine...
3.
Halvorsen Y, Conery A, Lock J, Zhou W, Freeman M
Diabetes Obes Metab
. 2023 Jul;
25(10):2954-2962.
PMID: 37409573
Aim: To evaluate the relative safety and effectiveness of bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes mellitus. Methods: In total, 317 participants were randomized...
4.
Freeman M, Halvorsen Y, Brown M
N Engl J Med
. 2023 May;
388(19):1821-1822.
PMID: 37163635
No abstract available.
5.
Freeman M, Bond M, Murphy B, Hui J, Isaacsohn J
Am J Cardiovasc Drugs
. 2023 Feb;
23(3):277-286.
PMID: 36790596
Background: Due to the high comorbidity of diabetes and hypertension, co-administration of metformin with anti-hypertensive drugs is likely. Baxdrostat is an aldosterone synthase inhibitor in development for the potential treatment...
6.
Freeman M, Halvorsen Y, Marshall W, Pater M, Isaacsohn J, Pearce C, et al.
N Engl J Med
. 2022 Nov;
388(5):395-405.
PMID: 36342143
Background: Aldosterone synthase controls the synthesis of aldosterone and has been a pharmacologic target for the treatment of hypertension for several decades. Selective inhibition of aldosterone synthase is essential but...
7.
Freeman M, Bond M, Murphy B, Hui J, Isaacsohn J
Hypertens Res
. 2022 Oct;
46(1):108-118.
PMID: 36266539
Baxdrostat is a selective inhibitor of aldosterone synthase designed for the treatment of disorders associated with elevated aldosterone. This study evaluated the safety, pharmacokinetics, and pharmacodynamics of multiple ascending doses...
8.
Halvorsen Y, Lock J, Frias J, Tinahones F, Dahl D, Conery A, et al.
Diabetes Obes Metab
. 2022 Sep;
25(1):293-301.
PMID: 36178197
Aim: To compare the effects of bexagliflozin tablets 20 mg, with those of optimally titrated glimepiride when used to treat adults with type 2 diabetes mellitus (T2DM) inadequately controlled by...
9.
Jeyaseelan S, Chu H, Young S, Freeman M, Worthen G
Infect Immun
. 2022 Mar;
90(4):e0001422.
PMID: 35285245
No abstract available.
10.
Zabaleta N, Dai W, Bhatt U, Herate C, Maisonnasse P, Chichester J, et al.
Cell Host Microbe
. 2021 Aug;
29(9):1437-1453.e8.
PMID: 34428428
The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that...